Document Detail

Pseudoprogression and Treatment Effect.
MedLine Citation:
PMID:  22440871     Owner:  NLM     Status:  Publisher    
The standard of care for newly diagnosed malignant glioblastoma entails postoperative radiotherapy and adjuvant chemotherapy with temozolomide. There has been an increase in the incidence of enhancing and progressive lesions seen on magnetic resonance imaging (MRI) following treatment. Conventional MRI with gadolinium contrast is unable to distinguish between the effects of treatment and actual tumor recurrence. New modalities have provided additional information for distinguishing treatment effects from tumor progression but are not 100% sensitive or specific in diagnosing progression. Novel radiographic or nonradiographic biomarkers with sensitivity and specificity verified in large randomized clinical trials are needed to detect progression.
Arman Jahangiri; Manish K Aghi
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-14
Journal Detail:
Title:  Neurosurgery clinics of North America     Volume:  23     ISSN:  1558-1349     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-3-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9008004     Medline TA:  Neurosurg Clin N Am     Country:  -    
Other Details:
Languages:  ENG     Pagination:  277-287     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Inc.
Department of Neurological Surgery, University of California at San Francisco (UCSF), 505 Parnassus Avenue, Room M779, San Francisco, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiology: Criteria for Determining Response to Treatment and Recurrence of High-Grade Gliomas.
Next Document:  The Role of BCNU Polymer Wafers (Gliadel) in the Treatment of Malignant Glioma.